Patients with T4N0 and T1‑3N1 colon cancer and a high preoperative carcinoembryonic antigen level benefit from adjuvant chemotherapy with oxaliplatin for 6 months.

导出 OA

翻译打印收藏纠错

作者： Hiroyuki,Inoue ^[1] ; Hiroki,Shimizu ^[2] ; Yoshiaki,Kuriu ^[2] ; Tomohiro,Arita ^[2] ; Kenji,Nanishi ^[2] ; Jun,Kiuchi ^[2] ; Takuma,Ohashi ^[2] ; Yusuke,Yamamoto ^[2] ; Hirotaka,Konishi ^[2] ; Ryo,Morimura ^[2] ; Atsushi,Shiozaki ^[2] ; Hisashi,Ikoma ^[2] ; Takeshi,Kubota ^[2] ; Hitoshi,Fujiwara ^[2] ; Eigo,Otsuji ^[2]

作者单位： Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan.;Department of Digestive Surgery, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto 605-0981, Japan. ^[1] Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan. ^[2]

关键词 adjuvant chemotherapy carcinoembryonic antigen colon cancer low-risk stage III oxaliplatin

DOI 10.3892/ol.2024.14759

PMID 39526306

发布时间 2024-11-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交